Shared on04 Aug 25Fair value Increased 2.86%
The upward revision in EQL Pharma’s price target reflects higher future P/E expectations despite stable profitability, indicating improved market confidence and raising the consensus fair value from SEK87.50 to SEK95.00. What's in the News EQL is expanding into Germany and the Netherlands by recruiting local experts to launch niche generics, aiming to replicate its Nordic strategy, with plans for future expansion into DACH and BeNeLux regions.